Ocular surface disease exacerbated glaucoma

Article

The rationale for optimizing the ocular surface in glaucoma patients

Case series

Discussion

OSD caused by the long-term use of topical anti-glaucoma medication, can lead to conjunctival inflammation, foreshortening and shrinkage12 and severe symptomatic cicatrisation, which is indistinguishable from ocular cicatricial pemphigoid (OCP). The terms drug-induced cicatricial conjunctivitis (DICC) and pseudopemphigoid have been used.13

As discussed glaucoma therapy causes OSD, however, it is also apparent that severe OSD in turn exacerbates glaucoma. The prevalence of glaucoma in patients with severe OSD has been found to be 65.7%.14 Proposed mechanisms for raised IOP in patients with OSD are increased conjunctival inflammation in patients using anti-glaucoma medications, vascular aetiologies and inflammation of the trabecular meshwork, and in addition inflammation and scarring of the episclera and sclera thereby impairing the outflow facility of the eye.15 In support of this inflammatory theory, a higher rate of inflammatory cell infiltrates and fibroblasts have been found in conjunctival and trabeculectomy tissue samples from patients who are chronically exposed to preserved glaucoma medications.16

The aim of our treatment approach was to break the destructive cycle of events (OSD may potentiate glaucoma and vice versa) and achieve improved IOP control and a healthy ocular surface. In all four patients an improvement in the OSD resulted in an improvement in the IOP control and stabilization of the visual field. This obviated the need for surgical intervention, during the study period. We feel our approach was successful possibly due to decreased inflammation of the trabecular meshwork, conjunctiva, episclera and sclera leading to improved outflow facility of the eye.

If glaucoma filtration surgery is subsequently required in our patients, the improvement in the ocular surface may contribute to the increased likelihood of a successful surgical outcome.

It may be argued that the reduction in IOP may have been due to improved compliance with treatment for two reasons; firstly as patient care was transferred to a specialist consultant-led glaucoma service and secondly due to a reduction in ocular discomfort following treatment of the OSD. We feel that these scenarios are unlikely because all four patients reported good compliance with treatment prior to being referred to the service. Furthermore, we recognize the limitations of our small retrospective clinic-based observation and the need for large robust randomized studies to test our hypothesis.

Nevertheless, we feel that this is an important finding in a group of patients in whom management can be challenging; glaucoma in patients with severe OSD is often refractive to medical therapy14 and the surgical success of glaucoma filtering surgery is compromised in this group.17 Our study raises a new argument for maintaining increased awareness of the signs and symptoms of OSD in patients with glaucoma and emphasizes the importance of timely diagnosis and treatment of a phenomenon we describe as 'OSD exacerbated glaucoma'.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.